Earnings Ahead

BMRN - BioMarin Pharmaceutical Inc.

76.22 -3.37 -4.23

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

About

Profile

BioMarin is a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to


Headquarters

Novato, California, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

BMRN



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • BioMarin Pharmaceutical Non-GAAP EPS of $0.46 misses by $0.02, revenue of $581.3M misses by $26.46M
  • BioMarin appoints Alexander Hardy as president and chief executive officer
  • BioMarin Pharmaceutical Q3 2023 Earnings Preview
  • Bernstein upgrades BioMarin to market perform, citing valuation
  • FDA approves use of BioMarin drug Voxzogo in children under 5
  • BioMarin a market perform at Raymond James due to growth concerns
  • BioMarin Pharmaceutical Non-GAAP EPS of $0.54 beats by $0.07, revenue of $595.3M in-line
  • BioMarin Pharmaceutical Q2 2023 Earnings Preview
  • BioMarin upgraded at BMO after FDA nod for hemophilia A therapy
  • BioMarin granted FDA nod for hemophilia A gene therapy
  • Eli Lilly, Humana among best health care names in defensive environment - BofA
  • BioMarin Pharmaceutical Non-GAAP EPS of $0.60 beats by $0.20, revenue of $596.4M beats by $26.01M
  • BioMarin Pharmaceutical Q1 2023 Earnings Preview
  • What is behind biotech M&A resurgence?
  • FDA to back accelerated approval pathway for gene therapies
  • BioMarin seeks FDA nod to expand use of its Voxzogo treatment in children under five
  • BioMarin's Roctavian gets FDA action date extended to end of June
  • BridgeBio soars 55% after Phase 2 data for achondroplasia candidate
  • BioMarin Pharmaceutical GAAP EPS of $0.00 beats by $0.07, revenue of $537.5M misses by $0.74M
  • BioMarin Pharmaceutical Q4 2022 Earnings Preview
Date Price Open High Low Vol Change
May 17 77.56 76.25
78.03
76.14
3.4M 0.77%
May 16 76.97 80.18
80.54
76.52
3.9M -4.27%
May 15 80.4 80.12
80.96
79.96
2.1M 0.94%
May 14 79.65 80.74
80.74
79.52
1.5M -1.06%
May 13 80.5 81.24
81.57
80.37
1.3M -0.65%
 
May 10 81.03 81.14
81.95
80.74
1.5M -0.84%
May 9 81.72 81.62
82.4
81.41
1.2M -0.13%
May 8 81.83 82
83.19
81.79
1.3M -0.91%
May 7 82.58 82.4
83.02
81.81
864K 0.60%
May 6 82.09 83.2
83.58
81.84
742K -0.45%
May 3 82.46 84.8
84.8
82.33
1.4M -1.6%
May 2 83.8 82.91
85.04
81.43
1.2M 0.59%
May 1 83.31 81.07
83.98
80.91
1.6M 3.16%
Apr 30 80.76 81.79
81.79
80.52
2.0M -1.67%
Apr 29 82.13 81.65
83.85
81.44
2.0M 1.51%
Apr 26 80.91 82.33
83.09
80.9
2.3M -1.53%
Apr 25 82.17 86.26
86.78
81
7.9M -9.9%
Apr 24 91.2 92.69
93.01
91
1.6M -0.93%
Apr 23 92.06 90.03
92.21
89.93
1.3M 2.87%
Apr 22 89.49 89.46
89.81
88.89
1.2M 0.97%
Apr 19 88.63 89.67
90.18
88.29
1.8M -1.6%
Apr 18 90.07 90.25
91.21
89.78
945K -0.44%
Apr 17 90.47 91.14
91.53
90.02
1.3M -0.44%
Apr 16 90.87 90.93
91.78
90.16
1.2M -0.7%
Apr 15 91.51 92.58
93.36
90.96
1.9M -0.77%
Apr 12 92.22 91.26
93.26
91.09
2.4M 0.83%
Apr 11 91.46 90.99
91.59
89.33
2.3M 1.39%
Apr 10 90.21 88.38
90.41
87.79
2.2M 1.38%
Apr 9 88.98 87.35
89.19
87.35
1.2M 1.95%
Apr 8 87.28 87
88.11
86.95
1.3M 0.38%
Apr 5 86.95 86.46
87.23
86.01
829K 0.07%
Apr 4 86.89 86.78
88.13
86.63
1.2M 0.13%
Apr 3 86.78 86.48
87.72
86.47
1.2M -0.02%
Apr 2 86.8 86.25
86.94
85.62
1.4M -0.34%
Apr 1 87.1 86.98
87.31
86.09
616K -0.27%
Mar 28 87.34 88.34
88.65
86.65
1.0M -1.43%
Mar 27 88.61 88.18
88.74
87.92
1.0M 0.99%
Mar 26 87.74 86.94
87.86
86.5
1.3M 1.41%
Mar 25 86.52 84.7
86.99
84.7
1.4M 1.63%
Mar 22 85.13 84.35
85.29
83.89
877K 1.21%
Mar 21 84.11 84.99
85.25
83.83
919K -0.77%
Mar 20 84.76 85.01
85.19
83.82
879K -0.6%
Mar 19 85.27 84.43
85.6
83.77
1.3M 1.74%
Mar 18 83.81 84.13
84.67
83.66
1.4M -0.07%
Mar 15 83.87 84.56
84.75
83.44
1.2M -0.62%
Mar 14 84.39 84.61
84.94
83.53
1.2M -0.45%
Mar 13 84.77 85.19
85.71
84.57
1.3M -0.48%
Mar 12 85.18 86.27
86.69
84.87
917K -0.95%
Mar 11 86 85.69
86.82
85.53
1.4M 0.06%
Mar 8 85.95 85.9
86.55
85.7
1.3M 0.07%
Mar 7 85.89 87.21
87.87
85.63
1.2M -1.01%
Mar 6 86.77 87.25
87.6
86.11
1.1M 0.87%
Mar 5 86.02 87.09
87.42
85.01
1.7M -1.94%
Mar 4 87.72 87.57
87.92
86.51
801K 0.67%
Mar 1 87.14 86.39
88.28
85.88
1.9M 1%
Feb 29 86.28 88.8
89
86.02
2.6M -2.4%
Feb 28 88.4 89.82
90.28
88.32
1.2M -2.51%
Feb 27 90.68 90.64
92.16
90.06
1.2M 0.64%
Feb 26 90.1 90.93
91.23
88.11
1.5M -1.25%
Feb 23 91.24 90.94
94.15
89.48
3.7M 0%